To strengthen its distribution, research, technical service and production network
Evonik Industries, a German manufacturer of specialist chemicals, is to combine its business in custom manufacturing of active pharmaceutical ingredients (Exclusive Synthesis), pharmaceutical amino acids (Rexim) and pharmaceutical polymers (Pharma Polymers).
The company will form a new Health Care business effective from 1 September. It will be part of Evonix’s Health & Nutrition business unit, headed by Reiner Beste.
‘The merger strengthens our distribution, research, technical service, and production network,’ said Beste.
‘This means that our products and services will be equally represented in key pharmaceutical markets in Europe, America, and Asia and that we can respond more comprehensively to customer requirements.’
Beste added that the move would create the framework for further strategic developments and strengthen partnerships with key customers.
Evonik has reorganised management to accommodate the move and Hans-Josef Ritzert, who has headed the Exclusive Synthesis & Pharma Amino Acids business since 2009, will become regional president, Greater China.
Evonik employs about 3,500 people in China and had a turnover exceeding b1bn in the region in 2010. Ritzert takes over from Dahai Yu, who was appointed to Evonik’s executive board in April.
Jean-Luc Herbeaux will head the new Health Care business. He has led Evonik’s Pharma Polymers business since 2009.
The Health Care business will be divided into three product lines: Pharma Polymers with the brands Eudragit and Resomer under the management of Thomas Riermeier. Klaus Sting will manage Exclusive Synthesis, and Thomas Hermann will head Rexim.